Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer

Karen J Taylor, Andrew Sims, Liang Liang, Dana Faratian, Morwenna Muir, Graeme Walker, Barbara Kuske, Mike Dixon, David A Cameron, David J Harrison, Simon P Langdon

Research output: Contribution to journalArticlepeer-review

Abstract

Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may well be expressed in a dynamic manner.
Original languageEnglish
Article numberR39
JournalBreast Cancer Research
Volume12
Issue number3
DOIs
Publication statusPublished - 2010

Keywords

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Blotting, Western
  • Breast Neoplasms
  • Drug Resistance, Neoplasm
  • Estradiol
  • Estrogen Antagonists
  • Estrogens
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • Mice, Nude
  • Oligonucleotide Array Sequence Analysis
  • Prognosis
  • RNA, Messenger
  • Receptors, Estrogen
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tamoxifen
  • Tumor Markers, Biological
  • Xenograft Model Antitumor Assays

Fingerprint

Dive into the research topics of 'Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer'. Together they form a unique fingerprint.

Cite this